Loading...

FITC Streptavidin FITC Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Fluorescein Isothiocyanate, SAv-FITC
Ave. Rating
Submit a Review
Product Citations
publications
SAV_FITC_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
  • SAV_FITC_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
405201 100 µg DKK250
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405202 500 µg DKK701
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-fluorescein isothiocyanate (FITC) is useful for detecting biotinylated antibodies. The excitation of FITC by 488 nm laser light induces a light emission maximum of 520 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The Streptavidin-FITC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin-FITC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the FITC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Streptavidin-FITC is useful as a second step reagent for indirect immunofluorescent staining, in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-FITC is 60 kD and Streptavidin alone is 52 kD.

Application References
  1. Schmutz S, et al. 2009. J. Immunol. 183:2217. PubMed
  2. Cho HY, et al. 2009. Immunol Lett. 127:39. PubMed
  3. de Wispelaere D, et al. 2012. J. Virol. 86:7072. PubMed
  4. Fukuoka A, et al. 2013. Int Immunol. PubMed
  5. Giltiay NV, et al. 2013. J Exp Med. 25:373. PubMed
  6. Lee JH, et al. 2014. J Rheumatol. 41:2425. PubMed
Product Citations
  1. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  2. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  3. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  4. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  5. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  6. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  7. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  8. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  9. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  10. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  11. Georgiadis C, et al. 2021. Leukemia. . PubMed
  12. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  13. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  14. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  15. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  16. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  17. Yang M 2012. J Virol. 86:7072. PubMed
  18. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  19. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  20. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  21. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  22. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  23. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  24. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  25. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  26. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  27. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  28. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  29. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  30. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  31. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  32. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  33. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  34. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  35. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  36. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  37. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  38. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  39. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  40. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  41. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  42. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  43. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  44. Hamester F, et al. 2022. Cells. 11:. PubMed
  45. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  46. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  47. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  48. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  49. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  50. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  51. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  52. Laurin M, et al. 2019. Elife. 8. PubMed
  53. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  54. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  55. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  56. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  57. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  58. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  59. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  60. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  61. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  62. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  63. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  64. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  65. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  66. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  67. Georgiadis C, et al. 2021. Leukemia. . PubMed
  68. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  69. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  70. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  71. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  72. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  73. Yang M 2012. J Virol. 86:7072. PubMed
  74. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  75. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  76. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  77. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  78. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  79. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  80. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  81. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  82. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  83. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  84. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  85. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  86. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  87. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  88. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  89. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  90. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  91. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  92. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  93. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  94. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  95. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  96. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  97. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  98. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  99. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  100. Hamester F, et al. 2022. Cells. 11:. PubMed
  101. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  102. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  103. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  104. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  105. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  106. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  107. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  108. Laurin M, et al. 2019. Elife. 8. PubMed
  109. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  110. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  111. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  112. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 06/17/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Fluorescein Isothiocyanate, SAv-FITC
Ave. Rating
Submit a Review
Product Citations
publications
SAV_FITC_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
  • SAV_FITC_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by Sav-FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
405201 100 µg DKK250
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405202 500 µg DKK701
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-fluorescein isothiocyanate (FITC) is useful for detecting biotinylated antibodies. The excitation of FITC by 488 nm laser light induces a light emission maximum of 520 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The Streptavidin-FITC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

Each lot of this Streptavidin-FITC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the FITC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Streptavidin-FITC is useful as a second step reagent for indirect immunofluorescent staining, in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-FITC is 60 kD and Streptavidin alone is 52 kD.

Application References
  1. Schmutz S, et al. 2009. J. Immunol. 183:2217. PubMed
  2. Cho HY, et al. 2009. Immunol Lett. 127:39. PubMed
  3. de Wispelaere D, et al. 2012. J. Virol. 86:7072. PubMed
  4. Fukuoka A, et al. 2013. Int Immunol. PubMed
  5. Giltiay NV, et al. 2013. J Exp Med. 25:373. PubMed
  6. Lee JH, et al. 2014. J Rheumatol. 41:2425. PubMed
Product Citations
  1. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  2. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  3. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  4. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  5. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  6. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  7. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  8. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  9. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  10. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  11. Georgiadis C, et al. 2021. Leukemia. . PubMed
  12. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  13. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  14. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  15. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  16. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  17. Yang M 2012. J Virol. 86:7072. PubMed
  18. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  19. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  20. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  21. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  22. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  23. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  24. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  25. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  26. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  27. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  28. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  29. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  30. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  31. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  32. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  33. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  34. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  35. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  36. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  37. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  38. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  39. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  40. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  41. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  42. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  43. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  44. Hamester F, et al. 2022. Cells. 11:. PubMed
  45. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  46. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  47. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  48. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  49. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  50. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  51. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  52. Laurin M, et al. 2019. Elife. 8. PubMed
  53. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  54. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  55. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  56. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
  57. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  58. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  59. Lorenzo-Martín LF, et al. 2022. Oncogene. 41:3341. PubMed
  60. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  61. Parnigoni A, et al. 2022. Matrix Biol. 109:140. PubMed
  62. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  63. Pymm P, et al. 2022. iScience. 25:105259. PubMed
  64. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  65. Luo Y, et al. 2023. Cell Discov. 9:40. PubMed
  66. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  67. Georgiadis C, et al. 2021. Leukemia. . PubMed
  68. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  69. Suarez-Calvet X, et al. 2021. FASEB J. 35:e21819. PubMed
  70. Krishack PA, et al. 2019. JCI Insight. 4:6. PubMed
  71. Sasaki N, Itakura Y, Toyoda M 2017. Stem Cell Res Ther. 10.1186/s13287-017-0534-1. PubMed
  72. Zaitouna AJ, et al. 2020. Bio Protoc. 10:e3655. PubMed
  73. Yang M 2012. J Virol. 86:7072. PubMed
  74. Sánchez-Salguero E, et al. 2021. Front Immunol. 12:712130. PubMed
  75. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  76. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  77. Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed
  78. Li S, et al. 2016. PLoS One. 11: 0163893. PubMed
  79. Lee J, et al. 2014. J Rheumatol. 41:2425. PubMed
  80. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  81. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  82. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  83. Yan R, et al. 2021. Cell Death Dis. 12:955. PubMed
  84. Noviski M, et al. 2018. Elife. 7:e35074. PubMed
  85. Zhang Y, et al. 2019. JCI Insight. 4:2. PubMed
  86. Schmutz S, et al. 2009. J Immunol. 183:2217. PubMed
  87. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  88. Cheng LS, et al. 2022. J Transl Med. 20:415. PubMed
  89. Shafiei-Jahani P, et al. 2021. Nat Commun. 12:2526. PubMed
  90. Galle-Treger L, et al. 2016. Nat Commun. 7:13202. PubMed
  91. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  92. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  93. Bülow JM, et al. 2022. Front Endocrinol (Lausanne). 13:1016057. PubMed
  94. Oda Y, et al. 2021. Sci Adv. 7:eabj6895. PubMed
  95. Li X, et al. 2021. Oncol Lett. 22:788. PubMed
  96. Wang Y, et al. 2022. Front Immunol. 13:847581. PubMed
  97. Buffolo M, et al. 2019. Cell Rep. 29:270. PubMed
  98. Cho H, et al. 2009. Immunol Lett. 127:39. PubMed
  99. Hensel JA, et al. 2019. Mol Ther Oncolytics. 12:41. PubMed
  100. Hamester F, et al. 2022. Cells. 11:. PubMed
  101. Lin Y, et al. 2012. PLoS One. 7:e30507. PubMed
  102. Fukuoka A, et al. 2013. Int Immunol. 25:373. PubMed
  103. Mödinger Y, et al. 2018. J Cell Mol Med. 22:6002. PubMed
  104. Giltiay N, et al. 2013. J Exp Med. 210:2773. PubMed
  105. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  106. SL C, et al. 2016. JCI Insight. 1: 83116. PubMed
  107. Sturmlechner I, et al. 2021. Science. 374:eabb3420. PubMed
  108. Laurin M, et al. 2019. Elife. 8. PubMed
  109. Lindsay RS, et al. 2021. J Exp Med. 218:. PubMed
  110. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  111. Zhu Z, et al. 2017. Int J Biochem Cell Biol. 10.1016/j.biocel.2017.04.003. PubMed
  112. Geng S, et al. 2016. Nat Commun. 7:13436. PubMed
Go To Top Version: 5    Revision Date: 06/17/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account